← Tuesday, 6 October 2026
75
Impact · ElevatedSEC 8-K · 6 Oct 2026, 21:15 UTC · scored from the filing text

RCKT secures $150M term loan facility from Hercules Capital

Why it matters

Rocket Pharmaceuticals entered a loan and security agreement with Hercules Capital on September 30, 2026, providing up to $150 million in senior secured term loans across five tranches, with $35 million funded immediately. This is material financing that extends RCKT's cash runway and provides access to capital tied to clinical milestones (Tranche 2 Milestone) and FDA approval of RP-A501 for Danon Disease (Approval Milestone), de-risking near-term operations and enabling continued development of its pipeline.

In plain language

Rocket Pharmaceuticals borrowed $150 million from Hercules Capital in a structured deal where it gets money now and more money if it hits clinical or FDA approval goals, giving the company cash runway through at least 2030.

Exposure
Price check
not measured: no fresh price at the time of scoringHow this is measured

Information only. AURA does not give buy or sell recommendations.